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Abstract
Introduction: Hyperglycemia represents an independent prognostic factor in critically ill non-diabetic patients but
not in those with diabetes. In this context, there is an ongoing debate on the benefit of an intensive insulin
therapy, particularly in diabetic patients. We tested the hypothesis that expression of the receptor for advanced
glycation end-products (RAGE), an important signal transduction receptor that elicits long-lasting nuclear factor
kappa B (NF-B) activation, may underlie this difference. RAGE expression is regulated by multiple ligands,
including high mobility group box-1 (HMGB-1), and is reflected by its released soluble form (sRAGE).
Methods: A predesigned analysis was conducted of prospectively collected samples from 76 hyperglycemic
critically ill patients (33 type-2 diabetes, 43 non-diabetes) aged ≥18 years with blood glucose of > 6.1 mmol/L
enrolled in a randomized controlled trial comparing intensive insulin therapy with conventional insulin therapy.
sRAGE and its ligand HMGB-1 together with IL-6, and soluble thrombomodulin (as markers of inflammation and
endothelial cell injury, respectively) were evaluated in ICU, at Days 1, 3, 5 and 7. Plasma samples from 18 healthy
subjects were used as controls.
Results: Both diabetic and non-diabetic hyperglycemic patients showed increased plasma sRAGE, HMGB-1 and
soluble thrombomodulin levels at the time of admission to ICU. Plasma IL-6 concentration was only increased in
non-diabetic patients. Plasma levels of sRAGE were higher in diabetic compared with non-diabetic patients.
Intensive insulin therapy resulted in a significant decrease of sRAGE and thrombomodulin at Day 7, in diabetic but
not in non-diabetic patients. Circulating sRAGE levels correlated positively with IL-6 and soluble thrombomodulin
levels and inversely with HMGB-1. Multivariate regression analysis demonstrated that sRAGE remains independently
correlated with HMGB-1 only in diabetic patients. Neither sRAGE nor any inflammatory markers are associated with
mortality.
Conclusions: These findings support the hypothesis that sRAGE release, time-course and response to intensive
insulin therapy differ between hyperglycemic diabetic and non-diabetic critically ill patients. Whether this difference
underlies the dissimilarity in clinical outcome of hyperglycemia in these two conditions warrants further studies.
Introduction
Hyperglycemia represents an important independent risk
factor for morbidity and mortality in critically ill
patients admitted to ICU [1,2]. Accordingly, the benefit
of strict control of blood sugar with intensive insulin
therapy (IIT) versus conventional insulin therapy (CIT)
has been greatly debated with some studies revealing
benefit and others lack of benefit [3-6]. Moreover, the
morbid consequences of hyperglycemia in critically ill
patients, and the clinical effects of IIT, have been shown
to differ according to diagnostic category [1-6]. In con-
trast to non-diabetic, hyperglycemia in ICU patients
with type-2 diabetes is not independently associated
with outcome, thus the benefit of IIT in this subpopula-
tion remains unclear [1,2].
Hyperglycemia in the presence of oxidant stress pro-
motes glycoxidation of intra- and extracellular proteins
and an accumulation of advanced glycation end-pro-
ducts (AGE) [7]. Engagement of AGE with their recep-
tor RAGE (a member of the immunoglobulin
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any medium, provided the original work is properly cited.superfamily of cell-surface molecules), elicits activation
of the transcription factor nuclear factor kappa B (NF-
B), expression of pro-inflammatory cytokines and
induction of oxidative stress [7,8]. The RAGE-mediated
inflammatory response has been implicated in micro-
and macrovascular injury in diabetes [9,10]. Recent stu-
d i e ss u g g e s tt h a tt h ep a t h o g e n i cr o l eo fR A G Ei sn o t
limited to diabetes but includes pathophysiological con-
ditions characterized by excessive inflammatory
response, such as sepsis and septic shock, acute lung
injury, and intestinal dysfunction complicating hemor-
rhagic shock [11-17].
RAGE is activated by a large number of ligands
including AGE, amyloid b-peptides, S-100 proteins and
HMGB-1 [7]. Preventing ligand-RAGE interaction by
the administration of recombinant soluble RAGE atte-
nuated intestinal dysfunction in mouse models of resus-
citated hemorrhagic shock and lipopolysaccharide
(LPS)-induced lung injury [12,18]. RAGE knockout mice
were shown to be resistant to septic shock induced by
cecal ligation and puncture [11,16]. These observations
suggest that the RAGE pathway is part of the systemic
inflammatory response in critical illnesses and play a
pathogenic role. Because the level of RAGE expression
is regulated by the presence of its ligands, such as AGE,
that are known to accumulate at a greater rate for a
longer time in diabetic compared with non-diabetic
patients, we hypothesized that the RAGE pathway may
underlie the difference in the clinical effects of hypergly-
cemia as well as response to IIT between diabetic and
non-diabetic patients admitted to ICU [19].
RAGE has several soluble receptor isoforms resulting
from alternative splicing of the full length mRNA or
proteolysis of the cell-surface receptor [20,21]. An
increased circulating total pool of sRAGE reflects
enhanced tissue expression of RAGE in type 2-diabetic
and non-diabetic subjects [22,23]. Hence, using an assay
that measures the extracellular domain of sRAGE, we
examined whether there is differential release of plasma
sRAGE between hyperglycemic diabetic and non-dia-
betic critically ill patients admitted to ICU. Furthermore,
the effects of conventional and intensive insulin therapy
on the time course of sRAGE expression and the release
of HMGB-1, thrombomodulin, and IL-6 were evaluated.
Materials and methods
Study population
The present investigation included 76 hyperglycemic cri-
tically ill (33 type-2 diabetes, 43 non-diabetes) consecu-
tive patients who stayed at least three days in the ICU.
Diagnosis of diabetes was based on the history as estab-
lished by the patient primary team prior to hospital
admission. The study population was part of a rando-
mized controlled study that evaluated the effects of IIT
versus CIT on the outcome of 523 critically ill patients.
Informed consent was obtained from all patients
included in the study before randomization. Insulin
therapy was titrated to maintain blood glucose concen-
trations between 4.4 and 6.1 mmol/L in the IIT group
and 10 and 11.1 mmol/L in the CIT group [6]. Patients
were eligible in the original study, if they were ≥18 years
and were hyperglycemic (blood glucose of > 6.1 mmol/L
during the first 24 hours of ICU admission). They were
not included if they had type I diabetes, diabetic ketoaci-
dosis, documented hypoglycemia on ICU admission or
in the same hospitalization, brain death, do-not-resusci-
tate status, terminal illness defined as expected survival
of less than four weeks as judged by the treating physi-
cian, post cardiac arrest, seizures within past six months,
pregnancy, liver transplantation, burn victims, readmis-
sion to ICU within the same hospitalization, expected
ICU length of stay (LOS) of < 24 hrs, inability to obtain
consent within the randomization window of 24 hrs of
ICU admission, and enrollment in a competing trial, as
published elsewhere [6]. The frequency of blood glucose
monitoring was once hourly and was increased to every
20 minutes when blood glucose levels decreased to ≤3.2
mmol/L, then was reduced to every two to four hours
when measurements were at the target level. The study
was approved by the Institutional Review Board of the
King Abdulaziz Medical City.
Blood sampling
Blood samples were collected in EDTA-treated tubes on
the day of admission to ICU, then on Days 3, 5 and 7.
The samples were immediately centrifuged at 4°C for 20
minutes at 1,600 g. Plasma samples were stored at -80°C
until assayed.
Measurement of sRAGE, HMGB-1, thrombomodulin and
IL-6 plasma levels
Plasma concentrations of sRAGE, HMGB-1, thrombo-
modulin and IL-6 were measured in accordance with
the manufacturers’ instructions using commercial ELISA
kits from R&D Systems (Minneapolis, MN, USA (Quan-
tikine human IL-6 and sRAGE)), Diagnostica Stago
(Asnieres, France (Asserachrom thrombomodulin)) and
Shino-test Corporation (Tokyo, Japan (HMGB-1)). Eigh-
teen plasma samples from healthy individuals were
included in the sRAGE, HMGB-1, thrombomodulin and
IL-6 assays.
Statistical analysis
Descriptive variables are given as the mean ± SE.
Skewed data are presented as median and interquartile
ranges (IQR 25th to 75th percentile). Comparisons were
performed using Wilcoxon and Kruskal-Wallis tests.
The mixed linear model was used to compare the
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used to determine the degree of the linear relationship
between the continuous variables. Linear and logistic
regression analyses were performed to determine the
associations between outcome, inflammatory markers
and clinical and biochemical variables. A multivariate
linear regression model was used to test the interaction
between renal function assessed by the calculated creati-
nine clearance and diabetes on plasma sRAGE levels.
Differences were considered significant at P <0 . 0 5 .T h e
statistical analysis of data was done by using the statisti-
cal software package SAS version 9.1.3 (Statistical Ana-
lysis System, SAS Institute Inc., Cary, NC, USA).
Results
Clinical characteristics of the study population
Table 1 shows that diabetic patients are significantly
older, with higher body mass index, blood sugar concen-
tration and severity of illness and lower creatinine clear-
ance on admission than non-diabetics. Hospital (but not
ICU) mortality is also significantly higher in diabetic
than non-diabetic patients. However, the present study
was not powered to evaluate clinical outcomes.
Circulating levels sRAGE, HMGB-1, thrombomodulin and
IL-6 in study population
On the day of admission to ICU, plasma sRAGE,
HMGB-1 and thrombomodulin levels are significantly
higher in all critically ill patients with or without
diabetes as compared with healthy control subjects (Fig-
ure 1). Plasma IL-6 levels are significantly higher in
non-diabetic but not in diabetic patients as compared
with values from healthy control (Figure 1).
Circulating levels sRAGE, HMGB-1, thrombomodulin and
IL-6 in diabetic and non-diabetic patients
Figure 1 shows that the plasma sRAGE concentration is
significantly higher and IL-6 lower when diabetic
patients are compared with those without diabetes
(median (IQR) 2,406 (1,534 to 3,613) vs. 1,302 (918 to
2,260 pg/ml); P = 0.003) and (61 (27 to 124) vs. 159 (59
to 224 pg/ml); P = 0.02), respectively. No differences in
HMGB-1 and soluble thrombomodulin is found
between these two groups of patients. Plasma sRAGE
levels correlate positively with plasma IL-6 and soluble
thrombomodulin levels and inversely with those of
HMGB-1 (Figure 2).
Effects of insulin therapy on sRAGE, HMGB-1,
thrombomodulin and IL-6 in diabetic and non-diabetic
patients
On the day of admission to ICU (day 1), the plasma
levels of sRAGE, HMGB-1, thrombomodulin and IL-6
are similar between IIT and CIT in diabetic and non-
diabetic patients (Figure 3). Compared with conven-
tional insulin therapy, IIT does not influence the time
course of sRAGE, HMGB-1, thrombomodulin and IL-6
in non-diabetic patients (Figure 3). However, in patients
Table 1 Baseline characteristics and outcome of diabetic and non-diabetic patients admitted in ICU
Diabetic Non-Diabetic
IIT
(n = 16)
CIT
(n = 17)
IIT
(n = 27)
CIT
(n = 16)
P
Age (years) 66.1 ± 3.5 65.9 ± 2.0 49.3 ± 4.5 43.4 ± 5.2 < 0.0001
Sex, male: female 6:10 7: 10 22:5 13:3 0.0001
BMI 31.2 ± 1.6 33.8 ± 2.6 25.1 ± 0.8 26.6 ± 1.0 0.0003
APACHE II score 28.6 ± 1.9 29.4 ± 1.7 22.3 ± 1.6 24.1 ± 2.0 0.001
Blood glucose (mmol/L) 15.0 ± 1.1 13.4 ± 0.9 11.1 ± 0.7 10.0 ± 0.4 < .0001
Creatinine (μmol/l) 178 ± 31 222 ± 47 119 ± 20 144 ± 41 0.14
Creatinine clearance (ml/min) 55 ± 10 52 ± 9 90 ± 9 95 ± 15 0.007
Admission category
Medical 16 16 21 14 0.15
Surgical 0 1 6 2 0.15
SOFA score (Day 1) 9.3 ± 0.7 10.9 ± 0.8 8.3 ± 0.6 10.0 ± 0.7 0.11
SOFA score (Day 3)
SEPSIS
7.4 ± 3.0 8.6 ± 3.7 7.0 ± 4.0 8.9 ± 2.6 0.25
ICU acquired sepsis 9 7 11 8 0.89
Length of hospital stay (days) 64.4 ± 14.4 42.6 ± 8.8 48.4 ± 10.0 48.3 ± 9.5 0.77
ICU mortality, no. 4 3 6 2 0.84
Hospital mortality, no. 91 17 3 0.001
Values represent mean (SE) in age, BMI, Acute Physiologic Score and Chronic Health Evaluation (APACHE II) score, blood glucose, and Sequential Organ Failure
Assessment (SOFA) score on admission to ICU. P-values represent the comparison between diabetic (n = 33) and non-diabetic patients (n = 43). Creatinine
clearance = (140 - age(yr))*weight(kg))/(72*serum Cr(mg/dL)) (multiply by 0.85 for women) [34].
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(903 (586 to 2,732) vs. 2,684 (1,956 to 4,312) pg/ml, P =
0.03) and thrombomodulin (61 (35 to 81) vs. 104 ng/ml,
P = 0.03) at day 7 post-admission, while creatinine clear-
ance did not significantly change over time (Figure 3).
Interrelationship between sRAGE, biochemical markers
and outcome in diabetic and non-diabetic patients
Multivariate regression analysis demonstrates that
sRAGE remains independently correlated with HMGB-1
only in diabetic patients (Table 2). Neither levels of
blood glucose and plasma creatinine, nor age, body
mass index (BMI), Acute Physiology and Chronic Health
Evaluation (APACHE) II score, creatinine clearance, and
Sequential Organ Failure Assessment (SOFA) score are
independently associated with sRAGE (Table 2). No sig-
nificant interaction between the creatinine clearance and
diabetes on plasma sRAGE levels was found (P = 0.08).
Uni- and multivariate logistic regression analyses
demonstrate that hyperglycemia is an independent
predictor of mortality in non-diabetic patients but not
in patients with diabetes. Neither sRAGE nor any
inflammatory markers are associated with mortality
(Table 3). However, these findings should be interpreted
cautiously due to the small sample size and the large
heterogeneity of the study groups.
Discussion
Findings from this study reveal that on admission to
ICU, critically ill patients with hyperglycemia display
elevated circulating levels of sRAGE, HMGB-1 and solu-
ble thrombomodulin. Circulating plasma IL-6 levels
were increased only in non-diabetic patients. This sug-
gest that sRAGE is a component of the host’s systemic
inflammatory response to hyperglycemic critical illness.
More important, the results show that diabetic and
non-diabetic patients display distinct sRAGE release and
time course pattern to acute illness as well as response
to IIT. The plasma sRAGE concentration is significantly
higher in diabetic patients than in those without
Figure 1 Plasma sRAGE, HMGB-1, thrombomodulin and IL-6 in diabetic and non-diabetics and control upon admission.
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Page 4 of 10diabetes. Administration of IIT attenuates significantly
the levels of sRAGE at ICU day 7 only in diabetic
patients. These findings suggest albeit indirectly that
RAGE pathway activation and response to IIT differ
between hyperglycemic diabetic and non-diabetic criti-
cally ill patients. Whether this accounts for the differ-
ence in clinical course and outcome observed between
these two conditions could not be ascertained because
  Diabetic  Non-diabetic 
r=0.31   p=0.008 
        0
      100
      200
      300
      400
      500
     600
      700
      800
      900
     1000
sRAGE (pg/ml)
0 1000 2000 3000 4000 5000 6000
I
L
-
6
 
(
p
g
/
m
l
)
 
        0
      100
      200
      300
      400
      500
sRAGE (pg/ml)
0 1000 2000 3000 4000  5000 6000
r=0.26   p=0.03 
    
    
    
T
h
r
o
m
b
o
m
o
d
u
l
i
n
 
(
n
g
/
m
l
)
 
        0
       10
       20
       30
sRAGE (pg/ml)
0 1000 2000 3000 4000 5000  6000
r=-0.40   p=0.005 
 
H
M
G
B
-
1
 
(
n
g
/
m
l
)
 
Figure 2 Correlation between plasma sRAGE, HMGB-1, soluble thrombomodulin and IL-6, respectively.rr e p r e s e n t st h ec o e f f i c i e n t
correlation.
Arabi et al. Critical Care 2011, 15:R203
http://ccforum.com/content/15/4/R203
Page 5 of 10of the discrepancy in baseline characteristics between
the two study groups. Nonetheless, the findings warrant
further investigations because of their potential clinical
and therapeutic implications. Indeed, if different
mechanistic pathways of inflammation are at play in
hyperglycemic diabetic and non-diabetic critically ill
patients, the use of a uniform therapeutic approach for
all patients may not be physiologically sound.
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Page 6 of 10RAGE is a pattern recognition receptor that has been
shown to contribute to both initiation and perpetuation
of inflammation in experimental sepsis [7,11,12,14,16].
In contrast to experimental studies, there is a paucity of
clinical data [24-26]. In healthy human volunteers, LPS
administration leads to increased plasma sRAGE levels
[24]. In patients with sepsis or septic shock, plasma
sRAGE was found elevated during the first 24 hours in
ICU, with the highest levels in non-survivors [26]. In
another study, plasma sRAGE was associated with out-
comes in patients with acute lung injury ventilated with
higher tidal volumes [17]. Findings in the present study
a r ei na c c o r d a n c ew i t ht h e s er e p o r t sb ys h o w i n gt h a t
sRAGE levels are elevated upon admission to ICU. It
also extends them by demonstrating that the rise of
plasma sRAGE levels remain sustained over a week and
Table 2 Univariate and multivariate linear regression analyses of factors associated with sRAGE in diabetic and non-
diabetics
Diabetic Non-diabetic
Univariate Multivariate Univariate Multivariate
Variable Estimate P Estimate P Estimate P Estimate P
Age (years) -10.991 NS -4.456 NS
Gender 769.540 NS 88.840 NS
BMI -4.315 NS -42.630 NS
APACHE II score 89.353 0.03 63.82 NS 28.739 NS
SOFA score 186.919 NS 60.331 NS
IL-6 (pg/ml) 3.479 0.01 1.22 NS 1.486 0.01 1.68 NS
Thrombomodulin (ng/ml) 4.165 NS 2.248 NS
HMGB-1 (ng/ml) * -544.690 0.001 -509.97 0.002 -56.697 0.03 -49.56 0.059
Creatinine (μmol/l) 1.834 NS 2.658 0.005 1.58 NS
Creatinine clearance (ml/minute) -6.957 NS -2.999 NS
Blood glucose (mmol/L) -37.363 NS -21.311 NS
PaO2/FIO2 (mm Hg) 0.638 NS 1.066 NS
INR 441.567 NS 16.071 NS
* P < 0.05 for both uni-and multivariate analysis
APACHE, Acute Physiologic Score and Chronic Health Evaluation; BMI, body mass index; HMGB-1, high mobility group box-1; IL-6, interleukin-6; INR, international
normalized ratio; PaO2/FIO2, ratio of partial pressure of oxygen to the fraction of inspired oxygen; SOFA, Sequential Organ Failure Assessment.
Table 3 Univariate and multivariate logistic regression analysis of factors associated with mortality in diabetic and
non-diabetics
Diabetic Non-diabetic
Univariate Multivariate Univariate Multivariate
Variable Estimate P Estimate P Estimate P Estimate P
Age (years) 0.012 NS 0.036 0.04 NS
Gender 0.464 NS 0.875 NS
BMI -0.075 NS -0.083 NS
APACHE II score 0.100 NS 0.124 0.02 NS
SOFA score * 0.345 0.02 0.357 0.03 0.009 NS
sRAGE (pg/ml) 0.0004 NS -0.00008 NS
IL-6 (pg/ml) 0.00003 NS 0.001 NS
Thrombomodulin (ng/ml) 0.004 NS 0.007 NS
HMGB-1 (ng/ml) -0.321 NS 0.046 NS
Creatinine (μmol/L) -0.002 NS 0.003 NS
Creatinine clearance (ml/minute) -0.0096 NS -0.028 0.01 -0.058 NS
Blood glucose (mmol/L)* 0.196 NS 0.514 0.003 0.03
PaO2/FiO2 (mm Hg) 0.0009 NS -0.006 NS
INR * 2.753 0.01 2.328 0.04 3.176 0.02 NS
* P < 0.05 for both uni-and multivariate analysis
APACHE, Acute Physiologic Score and Chronic Health Evaluation; HMGB-1, high mobility group box-1; IL-6, interleukin-6; INR, international normalized ratio; PaO2/
FIO2, ratio of partial pressure of oxygen to the fraction of inspired oxygen; SOFA, Sequential Organ Failure Assessment; sRAGE, soluble receptor for advanced
glycation end-products.
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Whether these long-lasting levels of plasma sRAGE
reflect persistent RAGE pathway activation and thereby
contribute to the perpetuation of inflammation in criti-
cally ill patients merit further studies.
Several studies have examined the association between
sRAGE levels and renal function, and revealed that
sRAGE is independently associated with decreased glo-
merular filtration rate [27-29], although the mechanisms
underlying this relationship are not well understood.
Both increased plasma sRAGE levels merely due to
reduced elimination by failing kidneys, as well as a result
of RAGE up-regulation to protect against AGE-accumu-
lation and induction of tissue damage have been postu-
lated. Most of these studies were confined to elderly
stable patients in chronic renal failure with or without
diabetes [27-29]. More recently, in patients with severe
traumatic injury, plasma levels of sRAGE were found to
predict the development of acute renal failure [30].
Taken together, these observations have prompted us to
examine the association between sRAGE levels and
renal function in our patients and the extent to which it
could explain the observed difference in plasma sRAGE
levels between the diabetic and non-diabetic patients.
Using a multivariate linear regression model, interaction
of diabetes with renal function could not be demon-
strated, which means that the difference in plasma
sRAGE levels on admission between diabetic and non-
diabetic patients could not be explained on the basis of
difference in renal function. Although, this finding
should be interpreted with caution due to the small
sample size of our study population, it may suggest that
circulating sRAGE levels in hyperglycemic critically ill
diabetic and non-diabetic patients reflect RAGE up-reg-
ulation. Although, the cellular source and precise role of
sRAGE in our patients remain unclear, sRAGE has been
demonstrated to exert a protective effect by working as
a decoy domain receptor averting ligands binding to
RAGE and, thereby, preventing inflammatory injury
[7,31]. In this context, we determined that plasma
HMGB-1 levels, a RAGE-ligand, and plasma IL-6 levels
as a marker of systemic inflammation were increased in
our study population. Surprisingly, we found that
although in more severe conditions on admission to
ICU, several patients with diabetes displayed a subdued
inflammatory response as assessed by circulating IL-6
levels compared with non-diabetic patients. This finding
is intriguing because there are very scarce data on the
systemic inflammatory response to critical illness in dia-
betic patients that result in ICU admission. Nonetheless,
earlier study demonstrated that the basal production of
IL-6 and TNF-a in cultured diabetic blood was mark-
edly depressed in comparison with non-diabetic samples
[32]. The release of IL-6 and TNF-a increased following
stimulation with LPS, but IL-6 remained significantly
lower in diabetic patients than in controls, thus lending
support to our observation [32]. The findings in the pre-
sent study also reveal that plasma sRAGE level is inde-
pendently correlated with HMGB-1 in diabetic patients
only. Hence, it is appealing to speculate that sRAGE
may have fulfilled its function as decoy in binding
HMGB-1 in diabetic patients. Whether this explains the
attenuated inflammatory response in this condition is
unclear and merits further study.
Previous study demonstrated that IIT protects the
endothelium of critically ill patients by down-regulating
iNOS gene expression; however, diabetic and non-dia-
betic patients were not segregated [33]. Indeed, the pre-
sent findings agree with this observation by showing
that both diabetic and non-diabetic critically ill patients
exhibit endothelial cell activation/injury as reflected by
increased levels of soluble thrombomodulin. The study
also reveals that IIT accelerates the decline of soluble
thrombomodulin levels, suggesting a comparable protec-
tive effect of the endothelium but only in diabetic
patients. Further, the concomitant decrease of sRAGE
with thrombomodulin raises a novel hypothesis that IIT
attenuated endothelial injury via RAGE down-regulation
in this subpopulation.
Some limitations of this study merit consideration.
First, the 76 patients studied comprise a small subgroup
from a total sample of 523 in the medial-surgical ICU.
Considering the inclusion and exclusion criteria of the
RCT, the results may not be extended to all hyperglyce-
mic critically ill patients whether they are diabetic or
not. Second, the immunoassay used in this study discri-
minates neither the RAGE that results from cleavage of
the cell-surface receptor nor the different sRAGE splice
variants [20]. Indeed, sRAGE isoforms have been shown
to vary among cell type, and to display different affinity
for RAGE ligands [20]. In our study, the cellular source
of sRAGE was unclear, thus, for future studies specific
assays for each splice variant would be required for
investigating the significance of sRAGE in clinical
samples.
Conclusions
Despite the limitations, the current study has revealed
that sRAGE release, time-course and response to IIT
differ between hyperglycemic diabetic and non-diabetic
critically ill patients. Whether this difference underlies
in part the dissimilarity in the immune response and
outcome to critical illness in these two conditions war-
rants further studies.
Key messages
￿ Both diabetic and non-diabetic hyperglycemic
patients display increased plasma sRAGE, HMGB-1
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Page 8 of 10and soluble thrombomodulin levels at the time of
ICU admission
￿ Plasma levels of sRAGE are higher in critically ill
diabetic patients compared with hyperglycemic non-
diabetic patients
￿ Intensive insulin therapy significantly decreases
plasma sRAGE and soluble thrombomodulin in dia-
betic patients, but not in those without diabetes
￿ RAGE pathway activation and response to IIT dif-
fer between hyperglycemic diabetic and non-diabetic
critically ill patients
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